TSC1 and breast cancer: Everolimus (Zortress®®, Afinitor®®, Disperz®®), an oral mTORC1 inhibitor currently used to treat advanced renal cell carcinoma, HR+ HER2− breast cancer, neuroendocrine tumors, and tumors associated with tuberous sclerosis, was evaluated in a Phase II trial (NCT00805129) in platinum-treated mUC with an ORR of only 5%, although patients with TSC1-mutant tumors demonstrated a significantly better response [58,59].